# Low BOK Expression Promotes Epithelial–Mesenchymal Transition and Migration via the Wnt Signaling Pathway in Breast Cancer Cells

**Authors:** Ling Liu, Tiantian He, Zhen Zhang, Wenjie Dai, Liyang Ding, Hong Yang, Bo Xu, Yitong Shang, Yu Deng, Xufeng Fu, Xing Du

PMC · DOI: 10.3390/ijms26157252 · International Journal of Molecular Sciences · 2025-07-27

## TL;DR

Low BOK levels in breast cancer cells increase cell migration and EMT by activating the Wnt signaling pathway.

## Contribution

This study reveals a novel mechanism by which BOK regulates EMT and migration via the Wnt pathway in breast cancer.

## Key findings

- BOK overexpression inhibits EMT and migration in breast cancer cells.
- BOK silencing activates the Wnt signaling pathway and promotes EMT markers.
- Low BOK expression enhances breast cancer progression through Wnt pathway activation.

## Abstract

The B-cell lymphoma 2 (Bcl-2)-related ovarian killer (BOK), a member of the Bcl-2 protein family, shares a similar domain structure and amino acid sequence homology with the pro-apoptotic family members BAX and BAK. Although BOK is involved in the development of various types of cancer, its mechanism of action in breast cancer remains unclear. This study found that BOK was involved in the process of MG132, inhibiting the migration and epithelial–mesenchymal transition (EMT) of breast cancer cells induced by transforming growth factor-β. Furthermore, interfering BOK reversed the inhibition of breast cancer cell migration and the EMT process by MG132. Additional studies revealed that BOK silencing promoted the expression of EMT-related markers in breast cancer cells, while BOK overexpression inhibited EMT and migration. Using RNA-seq sequencing and Western blotting, we confirmed that the Wnt signaling pathway is involved in BOK regulating the EMT process in breast cancer cells. Therefore, we conclude that low BOK expression promotes breast cancer EMT and migration by activating the Wnt signaling pathway. This study enhances our understanding of breast cancer pathogenesis and suggests that BOK may serve as a potential prognostic marker and therapeutic target for breast cancer.

## Linked entities

- **Genes:** BOK (BCL2 family apoptosis regulator BOK) [NCBI Gene 666], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596]
- **Chemicals:** MG132 (PubChem CID 462382)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578] {aka BAK, BAK-LIKE, BCL2L7, CDN1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, BOK (BCL2 family apoptosis regulator BOK) [NCBI Gene 666] {aka BCL2L9, BOKL}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}
- **Diseases:** Breast Cancer (MESH:D001943), cancer (MESH:D009369)
- **Chemicals:** MG132 (MESH:C072553)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12347190/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12347190/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12347190/full.md

---
Source: https://tomesphere.com/paper/PMC12347190